OOIR: Observatory of International Research

Papers

(The median citation count of Current Opinion in HIV and AIDS is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
The interplay between HIV and COVID-19: summary of the data and responses to date	136
Lenacapavir: a first-in-class HIV-1 capsid inhibitor	70
Ending the HIV epidemic for all, not just some: structural racism as a fundamental but overlooked social-structural determinant of the US HIV epidemic	46
A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV	40
Eliminating HIV reservoirs for a cure: the issue is in the tissue	38
Impact of Integrase inhibitors and tenofovir alafenamide on weight gain in people with HIV	33
Exosomes in HIV infection	26
Frailty: the current challenge for aging people with HIV	26
Cardiovascular toxicity of contemporary antiretroviral therapy	25
Promise, perils and cautious optimism: the next frontier in long-acting modalities for the treatment and prevention of HIV	22
Immunological effector mechanisms in HIV-1 elite controllers	21
HIV persistence in lymph nodes	19
Clinical consequences of asymptomatic cytomegalovirus in treated human immunodeficency virus infection	19
The first 6 months of HIV-SARS-CoV-2 coinfection: outcomes for 6947 individuals	19
HIV and cardiovascular disease: the role of inflammation	18
Technologies for HIV-1 drug resistance testing: inventory and needs	17
Key population perceptions and opinions about long-acting antiretrovirals for prevention and treatment: a scoping review	17
Adapting digital health interventions for the evolving HIV landscape: examples to support prevention and treatment research	15
Scaling up preexposure prophylaxis to maximize HIV prevention impact	15
The future of long-acting agents for preexposure prophylaxis	14
Mechanisms and primary prevention of atherosclerotic cardiovascular disease among people living with HIV	14
HIV care during the coronavirus disease-2019 pandemic in Shenzhen, China	14
How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention?	14
CD8+ T-cell responses in HIV controllers: potential implications for novel HIV remission strategies	13
Doravirine: its role in HIV treatment	13

The active human immunodeficiency virus reservoir during antiretroviral therapy: emerging players in viral persistence	12
The effect of HIV on COVID-19 vaccine responses	12
Broadly neutralizing antibodies for HIV treatment and cure approaches	11
New vector and vaccine platforms: mRNA, DNA, viral vectors	11
An update on neuropsychiatric adverse effects with second-generation integrase inhibitors and nonnucleoside reverse transcriptase inhibitors	11
Molecular epidemiology in the HIV and SARS-CoV-2 pandemics	10
Beyond criminalization: reconsidering HIV criminalization in an era of reform	10
From surviving to thriving: the current status of the behavioral, social, and psychological issues of aging with HIV	10
“Go”, “No Go,” or “Where to Go”; does microbiota dictate T cell exhaustion, programming, and HIV persistence?	10
Epidemiology of HIV drug resistance in low- and middle-income countries and WHO global strategy to monitor its emergence	10
Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy: Republication	9
Recent data on adipose tissue, insulin resistance, diabetes and dyslipidaemia in antiretroviral therapy controlled HIV-infected persons	9
Cardiovascular disease risk in women living with HIV	9
Context, COVID-19 and comorbidities: exploring emergent directions in syndemics and HIV research	9
Promises and challenges: cabotegravir for preexposure prophylaxis	9
Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection	9
Treatment of coronavirus disease 2019	8
Advances in cell and gene therapy for HIV disease: it is good to be specific	8
Public health services and intersectional stigma: a social sciences perspective with implications for HIV service design and delivery	8
Role of islatravir in HIV treatment and prevention: an update	8
The intersection of drug interactions and adverse reactions in contemporary antiretroviral therapy	8
Long COVID in people living with HIV	8
Hidden in plain sight: sex and gender in global pandemics	8
Moving toward equity: fostering transdisciplinary research between the social and behavioral sciences and implementation science to end the HIV epidemic	7
HIV and comorbidities – the importance of gut inflammation and the kynurenine pathway	7
An exploration of how broadly neutralizing antibodies might induce HIV remission: the ‘vaccinal’ effect	7
Potential and demonstrated impacts of the COVID-19 pandemic on sexually transmissible infections: Republication	7
Chimeric antigen receptor T-cell therapy for HIV cure	7
Divide and conquer: broadly neutralizing antibody combinations for improved HIV-1 viral coverage	7
Assessing proviral competence: current approaches to evaluate HIV-1 persistence	7
COVID-19 antibody development fueled by HIV-1 broadly neutralizing antibody research	7
Recent advances in HIV-associated chronic lung disease clinical research	7
Structural basis of severe acute respiratory syndrome coronavirus 2 infection	6
Causes and outcomes of hepatic fibrosis in persons living with HIV	6
Hepatotoxicity of contemporary antiretroviral drugs	6
A calculated risk: Evaluating HIV resistance to the broadly neutralising antibodies10-1074 and 3BNC117	6
The Coronavirus Disease 2019 pandemic: how does it spread and how do we stop it?	6
Fostemsavir: a first-in-class HIV-1 attachment inhibitor	6
Statins for primary cardiovascular disease prevention among people with HIV: emergent directions	6
Single-cell multiomic understanding of HIV-1 reservoir at epigenetic, transcriptional, and protein levels	5
Renal adverse drug reactions	5
Implementation of long-acting antiretroviral therapy in low-income and middle-income countries	5
The predictive value of macaque models of preexposure prophylaxis for HIV prevention	5
Prevention of heart failure, tachyarrhythmias and sudden cardiac death in HIV	5
Elite and posttreatment controllers, two facets of HIV control	5
Considerations for successful therapeutic immunization in HIV cure	5
Clinical consequences of weight gain during treatment for HIV infection	5
Impact of early antiretroviral therapy, early life immunity and immune sex differences on HIV disease and posttreatment control in children	5
Do sleep disturbances contribute to comorbidities in HIV?	5
The single-cell landscape of immunological responses of CD4+ T cells in HIV versus severe acute respiratory syndrome coronavirus 2	5

HIV-1 transcriptional modulation: novel host factors and prospective therapeutic strategies	5
Recent data on the role of antiretroviral therapy in weight gain and obesity in persons living with HIV	5
The severity of COVID-19 across the spectrum of HIV	5
Progress with induction of HIV broadly neutralizing antibodies in the Duke Consortia for HIV/AIDS Vaccine Development	4
Long-acting injectable HIV therapies: the next frontier: Republication	4
Behavioral and social interventions to promote optimal HIV prevention and care continua outcomes in the United States	4
A world of choices: preference elicitation methods for improving the delivery and uptake of HIV prevention and treatment	4
Delivery platforms for broadly neutralizing antibodies	4
Ten-year survival with analysis of gender difference, risk factors, and causes of death during 13 years of public antiretroviral therapy in rural Kenya: Republication	4
Viral, inflammatory, and reservoir characteristics of posttreatment controllers	4
Defining multimorbidity in people with HIV – what matters most?	4
Coronavirus disease-19 vaccine development utilizing promising technology	4
Safety of oral tenofovir disoproxil - emtricitabine for HIV preexposure prophylaxis in adults	3
Features of functional and dysfunctional CD8+ T cells to guide HIV vaccine development	3
Whole person HIV services: a social science approach	3
Advancing considerations of context in the evaluation and implementation of evidence-based biomedical HIV prevention interventions: a review of recent research	3
Update on treatment as prevention of HIV illness, death, and transmission: sub-Saharan Africa HIV financing and progress towards the 95–95–95 target	3
HIV cure: an acceptability scientific agenda	3
Discovery medicine – the HVTN's iterative approach to developing an HIV-1 broadly neutralizing vaccine	3
Promoting patient-centered care within HIV care settings in sub-Saharan Africa	3
What's new in bone disease and fractures in HIV?	3
Towards a molecular profile of antiretroviral therapy-free HIV remission	3
Clinical implementation of long-acting antiretroviral treatment in high-income countries: challenges and advantages	3
Current co-morbidities burden in patients living with HIV in low- and middle-income countries	3
Anticipating HIV viral escape – resistance to active and passive immunization	3
HIV and chronic lung disease	3
HIV and obesity: updates in management strategies	3
The origins of new SARS-COV-2 variants in immuncompromised individuals	3
Visualization of HIV-1 reservoir: an imaging perspective	3
Vaccinal effect of HIV-1 antibody therapy: dream or reality?	3
Long-acting preexposure prophylaxis in low- and middle-income countries: key considerations for implementation	3
The sounds of silencing: dynamic epigenetic control of HIV latency	2
The multifaceted nature of HIV tissue reservoirs	2
Editorial: Critical social and behavioral sciences perspectives on ending the HIV epidemic	2
Antibody interventions in HIV: broadly neutralizing mAbs in children	2
Targeting enhanced neutralizing antibody responses via increased germinal center activity: early-phase vaccine trials with novel clinical designs	2
HIV drug resistance in various body compartments	2
Gender and sex considerations in HIV and bone health	2
Nongovernmental organizations supporting the HIV service delivery response in Africa – an engine for innovation	2
Control groups for HIV prevention efficacy trials: what does the future hold?	2
Frailty phenotype is associated with antiretroviral exposure among older persons living with HIV	2
Harnessing immune cells to eliminate HIV reservoirs	2
Adaptation of advanced clinical virology assays from HIV-1 to SARS-CoV-2	2
Targeting HIV persistence in the tissue	2
Early diagnosis and population prevention of coronavirus disease 2019	2
HIV T-cell immunogen design and delivery	2
Development of screening assays for use of broadly neutralizing antibodies in people with HIV	2
‘Immunization during ART and ATI for HIV-1 vaccine discovery/development’	2